Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

GPCR Desensitization

GPCR Desensitization

G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

An Ugi-Joullié Platform for Medicinally Relevant 1,4-Dihydrobenzothiazines.

ChemMedChem·2026

Same author

One Face, Three Solutions: Structural Convergence in PD-L1 Inhibition across Antibodies, Macrocycles, and Small Molecules.

Journal of medicinal chemistry·2026

Same author

Clinical Associations of Cerebrospinal Fluid TMEM106B in Familial and Sporadic Frontotemporal Dementia.

JAMA neurology·2026

Same author

Neurocritical progression in amyotrophic lateral sclerosis: pathological relevance and validation.

Open life sciences·2026

Same author

Biosynthesized Silk-Amyloid-Mussel Proteins as Dissolution Recyclable Materials With Tunable Supercontraction.

Advanced materials (Deerfield Beach, Fla.)·2026

Same author

Restoring the 14-3-3/CRAF regulatory interaction in Noonan syndrome using molecular glues.

Proceedings of the National Academy of Sciences of the United States of America·2026

Same journal

Why Next-generation mechanistic models Will transform drug discovery: integrating efficacy and safety.

Expert opinion on drug discovery·2026

Same journal

Toward a nuanced framework for the Medical development of ibogaine and its analogues and derivatives: implications for psychopharmacology.

Expert opinion on drug discovery·2026

Same journal

From mitochondrial signal to discovery decision: a reserve-demand framework for translational risk assessment.

Expert opinion on drug discovery·2026

Same journal

Advances in 3D cell culture models for alzheimer's disease drug discovery.

Expert opinion on drug discovery·2026

Same journal

Are patient-derived models of amyotrophic lateral sclerosis a game changer for novel drug discovery?

Expert opinion on drug discovery·2026

Same journal

Unfolding prion misfolding and the challenge of identifying effective therapeutics: is there hope on the horizon?

Expert opinion on drug discovery·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jan 19, 2026

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

PROTACs- a game-changing technology.

Markella Konstantinidou¹, Jingyao Li¹, Bidong Zhang¹

¹Drug Design, University of Groningen , Groningen , The Netherlands.

Expert Opinion on Drug Discovery

|September 21, 2019

Summary

This summary is machine-generated.

Proteolysis-targeting chimeras (PROTACs) are novel bifunctional molecules that induce target protein degradation, offering a revolutionary approach to drug discovery beyond traditional inhibition. These molecules show promise for challenging targets and are poised to become a new therapeutic class.

Keywords:

Degradation PROTAC structural analysis

More Related Videos

qPCRTag Analysis - A High Throughput, Real Time PCR Assay for Sc2.0 Genotyping

qPCRTag Analysis - A High Throughput, Real Time PCR Assay for Sc2.0 Genotyping

Published on: May 25, 2015

The Combination of Transcranial Alternating Current Stimulation and Electroencephalogram

The Combination of Transcranial Alternating Current Stimulation and Electroencephalogram

Published on: October 10, 2025

Related Experiment Videos

Last Updated: Jan 19, 2026

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

qPCRTag Analysis - A High Throughput, Real Time PCR Assay for Sc2.0 Genotyping

qPCRTag Analysis - A High Throughput, Real Time PCR Assay for Sc2.0 Genotyping

Published on: May 25, 2015

The Combination of Transcranial Alternating Current Stimulation and Electroencephalogram

The Combination of Transcranial Alternating Current Stimulation and Electroencephalogram

Published on: October 10, 2025

Area of Science:

Drug discovery and development
Molecular pharmacology
Biochemistry

Background:

Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules designed to induce target protein degradation.
Unlike classical inhibitors, PROTACs leverage the cell's ubiquitin-proteasome system for targeted degradation.
This approach offers a new modality with the potential to revolutionize drug discovery.

Purpose of the Study:

To provide a comprehensive overview of PROTAC technology.
To analyze structural aspects, kinetics, and selectivity of PROTACs.
To examine specific PROTAC applications and emerging clinical data.

Main Methods:

Structural analysis based on published crystal structures.
Kinetic profiling of PROTAC activity.
Review of literature on homoPROTACs, Tau-targeting PROTACs, and clinical trial candidates.

Main Results:

PROTACs exhibit unique properties differentiating them from traditional inhibitors.
Analysis reveals insights into structural features, kinetics, and selectivity.
Early clinical trial data and specific PROTAC types are examined.

Conclusions:

PROTACs demonstrate remarkable efficacy and selectivity, even for challenging targets.
They offer a distinct mechanism of action by inducing protein degradation, not just inhibition.
Despite challenges, PROTACs are anticipated to emerge as a significant new therapeutic category.